Volume 15, Number 4—April 2009
Chagasic Cardiomyopathy in Immigrants from Latin America to Spain
Highlight and copy the desired format.
|EID||Pérez de Ayala A, Pérez-Molina J, Norman FF, López-Vélez R. Chagasic Cardiomyopathy in Immigrants from Latin America to Spain. Emerg Infect Dis. 2009;15(4):607-608. https://dx.doi.org/10.3201/eid1504.080938|
|AMA||Pérez de Ayala A, Pérez-Molina J, Norman FF, et al. Chagasic Cardiomyopathy in Immigrants from Latin America to Spain. Emerging Infectious Diseases. 2009;15(4):607-608. doi:10.3201/eid1504.080938.|
|APA||Pérez de Ayala, A., Pérez-Molina, J., Norman, F. F., & López-Vélez, R. (2009). Chagasic Cardiomyopathy in Immigrants from Latin America to Spain. Emerging Infectious Diseases, 15(4), 607-608. https://dx.doi.org/10.3201/eid1504.080938.|
To the Editor: An estimated 8 million persons in 21 countries in the Western Hemisphere are infected by Trypanosoma cruzi, the cause of Chagas disease. The global infection rate is 1.4% (1) and varies by geographic area from 0.1% to 45.4% (2). After infection, organ involvement, predominantly cardiac disease, will develop in 20%–30% after 10–30 years (3).
Worldwide, Spain is second to the United States in having the largest number of immigrants from Latin America (4). In 2008, immigrants accounted for 11.3% of the population in Spain. A total of 1,607,699 were from T. cruzi–endemic areas; of these, 239,942 are from Bolivia (5), the country with the highest prevalence of T. cruzi infection (2).
Imported Chagas disease may emerge in Europe. Chronic Chagas disease was diagnosed in 120 patients during 2003–2008 at the Tropical Medicine Unit, Ramón y Cajal Hospital, in Madrid, Spain. Of these patients, 22.5% had cardiac involvement and 95.8% were from Bolivia. Similar data have been observed in other cities in Spain and Europe (6,7).
Successful control programs for Chagas disease have been conducted in Latin America in recent years. However, because this disease may have a latency period of many years, infection in immigrants may vary depending on background prevalence in the country of origin.
To calculate Chagas disease prevalence in Latin American immigrants, we considered different values. The number of registered immigrants in Spain according to country of origin for 2007 (5) and infection prevalence rates in blood donors for different disease-endemic countries (1993–2002) (2) were recorded. The lowest and highest prevalence rates for each country were applied to the number of immigrants from that country living in Spain. Thus, estimates were obtained for the number of potentially infected immigrants for each country of origin. From these figures, a range for the total number of potentially infected immigrants was calculated. Taking into account that all blood donors, but only 80.2% of registered immigrants in Spain (5), are adults, we applied an age-correction factor of 80.2% to these figures (multiplying 80.2% by the total) (Table).
Two possible scenarios were then defined to estimate the number of chagasic cardiomyopathies that may arise in the immigrant population. For the best-case scenario, the lowest calculated number of potentially infected immigrants (29,485) was used with the lowest rate of progression to cardiac involvement (20%). For the worst-case scenario, the highest number of infections (98,030) was calculated and used with a 30% risk of progression to cardiac disease. On the basis of these estimates, 5,897–29,409 cases of chagasic cardiomyopathy may be diagnosed in the near future in Spain.
Information on the prevalence of T. cruzi infection has changed over time, and the immigrant populations may not be a representative group from disease-endemic areas. Thus, extrapolating these figures to the current population in Spain may pose some problems. However, prevalence data in Bolivia (9.9% in 2001) (2), the country with the highest rates of infection, are consistent with data from Spain (2005–2006), which reported a seroprevalence rate of 10.2% in blood donors from Bolivia (8).
In recent years, vector control programs in Chagas disease–endemic countries have influenced infection rates. However, most adult immigrants became infected during their childhood, particularly in Bolivia, before any vector control programs were started. Thus, estimated infection rates in adults should not be greatly biased. In a recent study in Spain, the average age of patients with Chagas disease who came to clinics was 35 years (6), a finding similar to that seen at our unit. At this age, one might expect infected patients to show cardiac involvement caused by Chagas disease, as well as other manifestations such as megaesophagus and megacolon (3).
Screening for Chagas disease should be recommended to all Latin American migrants, especially those from Bolivia. This screening would enable early treatment for persons in the chronic asymptomatic phase or those with mild cardiac involvement, persons for whom treatment has been recommended (9).
Current legislation in Spain makes screening all at-risk blood donors mandatory (10). However, screening of pregnant women from Chagas disease–endemic countries is not compulsory, although 46.8% of immigrants in Spain are female and birth rates in this group are higher than the national average for Spain (5). Detection of antibodies to T. cruzi during pregnancy would also be a useful public health strategy because it would enable early specific treatment of affected newborns. Screening of blood or organ donors would also be necessary in countries where there is no transmission by vectors.
T. cruzi infection may become a public health problem in countries in Europe that receive immigrants from disease-endemic areas. Thus, chagasic cardiomyopathy may soon have a serious effect on public health in Spain.
This study was supported by the Red de Investigación de Centros de Enfermedades Tropicales RED: RD06/0021/0020.
- World Health Organization. Reporte del grupo de trabajo científico sobre la enfermedad de Chagas. TDR/GTC/09. Buenos Aires: The Organization; 2005.
- Schmunis GA, Cruz JR. Safety of the blood supply in Latin America. Clin Microbiol Rev. 2005;18:12–29.
- Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis. 2001;1:92–100.
- Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz. 2007;102:75–85.
- Instituto Nacional de Estadística. Spain census data. Madrid; 2008 [cited 2008 Dec 12]. Available from http://www.ine.es
- Manzardo C, Trevino B, Gomez i Prat J, Cabezos J, Mongui E, Claveria I, Communicable diseases in the immigrant population attended to in a tropical medicine unit: epidemiological aspects and public health issues. Travel Med Infect Dis. 2008;6:4–11.
- Lescure FX, Canestri A, Melliez H, Jaureguiberry S, Develoux M, Dorent R, Chagas disease, France. Emerg Infect Dis. 2008;14:644–6.
- Piron M, Verges M, Munoz J, Casamitjana N, Sanz S, Maymo RM, Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion. 2008;48:1862–8.
- Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med. 2006;144:724–34.
- Ministerio de Sanidad y Consumo. Real decreto 1088/2005 por el que se establecen los requisitos técnicos y condiciones mínimas de la hemodonación y de los centros y servicios de transfusión. In: Boletín oficial del estado. Madrid: Ministerio de Sanidad y Consumo; 2005. p.31288–304.
- Table. Immigrants in Spain from Chagas disease–endemic countries in South America potentially infected with Trypanosoma cruzi, 1993–2002
Please use the form below to submit correspondence to the authors or contact them at the following address:
Rogelio López-Vélez, Infectious Diseases, Ramón y Cajal Hospital, Carretera de Colmenar 9, 1, Madrid, Spain
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: December 10, 2010
- Page last updated: December 10, 2010
- Page last reviewed: December 10, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)